NEW YORK CITY, NY / ACCESS Newswire / December 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the ...

San Diego news; when you want it, where you want it. Get local stories on politics, education, health, environment, the border and more. New episodes are ready weekday mornings. Hosted by Debbie Cruz ...

Pacira BioSciences (PCRX) has taken legal action against The WhiteOak Group and Qilu Pharmaceutical, resulting in a 30-month delay for FDA approval of generic versions of its flagship drug, EXPAREL.

BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...

In October 2024, InvestingPro’s Fair Value models identified Pacira BioSciences (NASDAQ:PCRX) as significantly undervalued, signaling a potential opportunity for investors. Since that alert, the stock ...

Barclays initiated coverage of Pacira (PCRX) with an Equal Weight rating and $27 price target The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying ...

) has been revised to $30.77 / share. This is a decrease of 18.47% from the prior estimate of $37.74 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

New Suit - Patent case: Pacira Pharmaceuticals, Inc. and Pacira Biosciences, Inc. v. Qilu Pharmaceutical (hainan) Co., Ltd., and Qilu Pharma, Inc. 2:25-cv-06742 ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...